ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 565,62
-0,50%
Dow Jones
41 914,75
-0,70%
DAX
18 918,50
-0,36%
Brent Oil
72,845
-0,47%
Bitcoin
63 383,46
0,40%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Pfizer Inc (PFE)

  7. Pfizer Inc (PFE) Actualités

PFE

Pfizer (PFE)

Pfizer Inc
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:PFE
DateHeureSourceTitreSymboleSociété
25/09/202423h00Business WirePfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide MarketsNYSE:PFEPfizer Inc
20/09/202414h11Business WirePfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European UnionNYSE:PFEPfizer Inc
17/09/202423h01AllPennyStocks.comTargeting Cancer's Achilles Heel: AI-Driven DDR Therapies Offer HopeNYSE:PFEPfizer Inc
17/09/202416h00Business WirePfizer Invites Public to View and Listen to Webcast of October 29 Conference Call with AnalystsNYSE:PFEPfizer Inc
16/09/202419h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:PFEPfizer Inc
14/09/202414h45Business WirePfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer CachexiaNYSE:PFEPfizer Inc
14/09/202410h15Business WirePfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung CancerNYSE:PFEPfizer Inc
13/09/202422h49Edgar (US Regulatory)Form SC TO-I/A - Tender offer statement by Issuer: [Amend]NYSE:PFEPfizer Inc
11/09/202412h45Business WirePfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024NYSE:PFEPfizer Inc
28/08/202416h00Business WirePfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare ConferenceNYSE:PFEPfizer Inc
27/08/202412h45Business WirePfizer Launches PfizerForAll™, a Digital Platform that Helps Simplify Access to HealthcareNYSE:PFEPfizer Inc
23/08/202414h20IH Market NewsCruise and Uber Join Forces for Robotaxis, Alibaba Shifts Primary Listing to Hong Kong, Altria Hikes Dividend 4.1%NYSE:PFEPfizer Inc
22/08/202420h15Business WirePfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 VaccineNYSE:PFEPfizer Inc
16/08/202412h45Business WirePfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of AgeNYSE:PFEPfizer Inc
13/08/202411h43IH Market NewsDell Stock Slide Offers Opportunities; Trump and Musk hold talks on X; GM Restructures China Operations, and MoreNYSE:PFEPfizer Inc
12/08/202417h42Edgar (US Regulatory)Form SC TO-I - Tender offer statement by IssuerNYSE:PFEPfizer Inc
12/08/202412h45Business WirePfizer Announces Top-Line Results of ABRYSVO® for RSV in Immunocompromised AdultsNYSE:PFEPfizer Inc
06/08/202400h12Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NYSE:PFEPfizer Inc
05/08/202421h54Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:PFEPfizer Inc
02/08/202415h49Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNYSE:PFEPfizer Inc
31/07/202414h01PR Newswire (Canada)ViiV Soins de santé annonce des données positives montrant que la bithérapie DOVATO est aussi efficace que la trithérapie BIKTARVY pour le traitement d'entretien du VIH-1NYSE:PFEPfizer Inc
31/07/202414h01PR Newswire (Canada)ViiV Healthcare announces positive data demonstrating 2-drug regimen DOVATO is as effective as 3-drug regimen BIKTARVY for maintenance therapy of HIV-1NYSE:PFEPfizer Inc
30/07/202423h17Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNYSE:PFEPfizer Inc
30/07/202415h23IH Market NewsFutures Pointing To Another Lackluster Session On Wall StreetNYSE:PFEPfizer Inc
30/07/202414h04Edgar (US Regulatory)Form 8-K - Current reportNYSE:PFEPfizer Inc
30/07/202412h45Business WirePfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 GuidanceNYSE:PFEPfizer Inc
30/07/202412h06IH Market NewsU.S. Futures Climb Before Fed Meeting; Oil Prices Drop on China Demand WorriesNYSE:PFEPfizer Inc
30/07/202412h03IH Market NewsF5 Shares Rise 15%; Diageo Falls 10% on Annual Sales Decline; BP Boosts Dividend and Buyback ProgramNYSE:PFEPfizer Inc
29/07/202422h44IH Market NewsU.S. Stocks Finish Choppy Trading Session Little ChangedNYSE:PFEPfizer Inc
25/07/202416h48Business WireEuropean Commission Approves Pfizer’s DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia BNYSE:PFEPfizer Inc
 Showing the most relevant articles for your search:NYSE:PFE

Dernières Valeurs Consultées

EU
GLE
Societe Generale
NASDAQ
MSFT
Microsoft
EU
ML
Michelin
NYSE
NKE
Nike
EU
AI
Air Liquide
COIN
ADAUSD
Cardano
COIN
SOLUSD
Solana
NYSE
JPM
JP Morgan Chase
EU
CAP
Capgemini
NYSE
DIS
Walt Disney
EU
BEL20
Bel 20
EU
VIV
Vivendi
EU
ORA
Orange
EU
DG
Vinci
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés